Lilly’s experimental breast cancer drug slips in trial
Lilly’s experimental breast cancer therapy abemaciclib has failed to hit interim efficacy targets in a late-stage combination trial, but the study will continue as planned on the recommendation of an independent data monitoring committee.
Read More
